Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q4 EPS of $0.30, $0.59 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $42.1 million versus the consensus estimate of $28.61 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.